The 29th Conference on Retroviruses and Opportunistic Infections (CROI) will be held from February 12 to 16, 2022, and will include the best and most consequential original research, including HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions. 

CROI Going Hybrid in 2022: CROI is currently planned to include both virtual and in-person participation. The in-person component, hosted in Denver, Colorado, USA, will feature additional sessions and networking opportunities. The CROI Scientific Program Committee will monitor the COVID-19 pandemic carefully in terms of changes in the safety and practicality of hosting an in-person component. Additional information will be posted as it becomes available. The Preliminary Agenda below is under development and will be updated as additional information becomes available. On most days, sessions will begin at 8:30 AM Mountain Time (Denver, CO, USA). Click Here to Convert to Your Local Time.

Saturday, February 12, 2022

Program Committee Workshop for New Investigators and Trainees
The workshop provides an overview of the major themes to be presented at CROI, including the current state-of-the-art of selected areas of basic and clinical research in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions.

Sunday, February 13, 2022

Opening Session

  • Martin Delaney Presentation

    The Martin Delaney Presentation recognizes the important contributions of community advocacy and engagement to HIV/AIDS research.
  • Bernard Fields Lecturer
    Dan H. Barouch
    , Beth Israel Deaconess Medical Center, Boston, MA, USA
    The Bernard Fields Lecture recognizes a basic scientist for important and relevant contributions to the fields of virology and viral pathogenesis.
  • N’Galy-Mann Lecturer 
    Beatriz Grinsztejn, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
    The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for important and relevant work in the fields of epidemiology or clinical research.
  • Conversation with Dr Rochelle Walensky
    Rochelle P. Walensky, Centers for Disease Control and Prevention, Atlanta, GA, USA
    A special moderated discussion with Dr Walensky, the 19th Director of the Centers for Disease Control and Prevention, will focus on the US response to the COVID-19 pandemic.

Concurrent Technical Workshops
Live presentations with question and answer periods

  • Frontiers in Laboratory Sciences
  • Clinical Trial Design and Analysis
  • Case-Based Liver Workshop

Monday, Tuesday, and Wednesday, February 14, 15, and 16, 2022

The primary conference days feature 4 hours of presentations for virtual and in-person attendees who travel to Denver. Additional programming and networking opportunities will be available live to in-person attendees.

Live Content for In-Person and Virtual Attendees (4 hours each day)

  • Welcome: A roadmap to the day’s content
  • Plenary Session (1 hour): State-of-the-art presentations by 2 plenary speakers each day
Plenary Speakers on Monday, February 14, 2022

HIV Non-Human Primate Models for Studies of Virus Pathogenesis, Persistence, and Cure
Michaela Muller-Trutwin, Institute Pasteur, Paris, France

Children Exposed to HIV but Uninfected: Balancing the Scales
Andrew J. Prendergast, Queen Mary University of London, London, United Kingdom

Plenary Speakers on Tuesday, February 15, 2022

New Insights Into HIV RNA Biology
Michael F. Summers, University of Maryland Baltimore County, Baltimore, MD, US

Understanding the Epidemiology of COVID-19: A Global Perspective
Muge Cevik, University of St Andrews, St Andrews, United Kingdom

Plenary Speakers on Wednesday, February 16, 2022

New Antiretrovirals and the Future of HIV Treatment and Prevention
Chloe Orkin, Queen Mary University of London, London, United Kingdom

Past and Future of HIV Vaccines
Mark Feinberg, International AIDS Vaccine Initiative (IAVI), New York, NY, USA

  • Concurrent Oral Abstract Sessions (2 hours): New abstract-driven research on HIV infection and related conditions as well as research on SARS-CoV-2
  • Concurrent Interactive Sessions (1 hour): State-of-the-art presentations offered in a mixture of highly interactive formats (eg, dialogues with experts, point-counterpoint debates, panels, and facilitated discussions) with audience questions and answers

Live Content for In-Person Attendees

Each day will feature special content for in-person attendees. Sessions will be available afterward to virtual attendees as on-demand content.

  • Symposia: State-of-the-art presentations in basic science, treatment, and prevention of HIV, related infections, and COVID-19
  • Other Special Sessions: Live Poster Discussions and more

New Investigator Networking: New investigators and trainees will have the opportunity to sign up for small networking sessions with leaders in HIV research, treatment, and prevention.

Attendee Networking: Special networking opportunities will be made available to attendees who travel to the in-person conference in Denver.